CONFIDENTIAL TREATMENT REQUESTED LICENSE AGREEMENTLicense Agreement • January 15th, 2016 • AveXis, Inc. • Biological products, (no disgnostic substances) • New York
This LICENSE AGREEMENT (“Agreement”) is entered into as of March 21, 2014 (“Effective Date”) by and between ReGenX Biosciences, LLC, a limited liability company organized under the laws of the State of Delaware, with offices at 750 17th Street, NW, Suite 1100, Washington, DC 20006 (“Licensor”), and AveXis, Inc. (formerly known as BioLife Cell Bank, Inc.), a corporation organized under the laws of the State of Delaware, with offices at 4925 Greenville Avenue, Suite 604, Dallas, TX 75206 (“Licensee”). Licensor and Licensee are hereinafter referred to individually as a “Party” and collectively as the “Parties.”
AVEXIS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • January 15th, 2016 • AveXis, Inc. • Biological products, (no disgnostic substances) • Illinois
This Employment Agreement (the “Agreement”) is entered into as of August 7, 2015, by and between Sukumar Nagendran, M.D. (the “Executive”) and AveXis, Inc. (the “Company”).
CONFIDENTIAL TREATMENT REQUESTED NON-EXCLUSIVE LICENSE AGREEMENTNon-Exclusive License Agreement • January 15th, 2016 • AveXis, Inc. • Biological products, (no disgnostic substances) • New York
This Non-Exclusive License Agreement (this “Agreement”) is made and entered into as of this 29th day of May, 2015 (the “Effective Date”), by and between ASKLEPIOS BIOPHARMACEUTICAL, INC., a North Carolina corporation with an address at 45 North Chatham Parkway, Chapel Hill, NC 27517 (“AskBio”), and AVEXIS, INC., a Delaware corporation with an address at 4925 Greenville Avenue, Suite 604, Dallas, Texas 75206 (“AveXis”). AskBio and AveXis may be referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT BETWEEN NATIONWIDE CHILDREN’S HOSPITAL AND AVEXIS, INC.Exclusive License Agreement • January 15th, 2016 • AveXis, Inc. • Biological products, (no disgnostic substances) • Ohio
This Amended and Restated Exclusive License Agreement (this “Agreement”) is entered into as of the last date of the signatures below (the “A&R Effective Date”) by and between Nationwide Children’s Hospital, a nonprofit Ohio corporation (“Children’s”) and AveXis, Inc., formerly known as BioLife Cell Bank Inc., a Delaware corporation having offices at 2275 Half Day Rd, Suite 160, Bannockburn, IL 60015 (“Licensee”).
CONSULTING AGREEMENTConsulting Agreement • January 15th, 2016 • AveXis, Inc. • Biological products, (no disgnostic substances)
This Consulting Agreement (this “Agreement”) dated as of January 28, 2014 (the “Effective Date”) is made by and between Dr. Brian K. Kaspar (the “Consultant”) and BioLife Cell Bank, Inc., a Delaware corporation (the “Company”).
OFFICE LEASEOffice Lease • January 15th, 2016 • AveXis, Inc. • Biological products, (no disgnostic substances) • Illinois
THIS LEASE, made and entered into in Bannockburn, Illinois as of this 31st day of July, 2015 by and between WANXIANG BANNOCKBURN, L.L.C., an Illinois limited liability company, (hereinafter referred to as the “Landlord”), and AveXis, Inc., an Delaware corporation (hereinafter referred to as the “Tenant”);
Severance Benefits Agreement John CarbonaSeverance Benefits Agreement • January 15th, 2016 • AveXis, Inc. • Biological products, (no disgnostic substances)
This agreement is being entered into by AveXis, Inc. (the “Company”) and John Carbona (“Mr. Carbona”), with reference to the employment agreement between the Company and Mr. Carbona dated August 7, 2014 (the “Employment Agreement”). Capitalized terms used but not defined herein shall have the meanings set forth in the Employment Agreement.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • January 15th, 2016 • AveXis, Inc. • Biological products, (no disgnostic substances) • Texas
This Executive Employment Agreement (this “Agreement”) is made and entered this 7th day of August, 2014 (the “Effective Date”), by and between AveXis, Inc., a Delaware corporation (the “Employer”), and John A. Carbona, an individual residing in the State of Texas (the “Executive”).
THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTAdoption Agreement • January 15th, 2016 • AveXis, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”), is made as of the 3rd day of September, 2015, by and among AVEXIS, INC., a Delaware corporation (the “Company”), the investors listed on Schedule A hereto (the “Investors”) and each of the stockholders listed on Schedule B hereto (the “Key Holders”).
RESTRICTED STOCK PURCHASE AGREEMENTRestricted Stock Purchase Agreement • January 15th, 2016 • AveXis, Inc. • Biological products, (no disgnostic substances) • Texas
This Restricted Stock Purchase Agreement (this “Agreement”‘) is made effective as of January 28, 2014, (the “Effective Date”) by and between BioLife Cell Bank, Inc., a Delaware corporation (the “Company”), and Dr. Brian K. Kaspar (“Purchaser”).
AVEXIS, INC. STOCK INCENTIVE AWARD AGREEMENTStock Incentive Award Agreement • January 15th, 2016 • AveXis, Inc. • Biological products, (no disgnostic substances) • Texas
This Stock Incentive Award Agreement (the “Agreement”) is effective as of , between AveXis, Inc., a Delaware corporation formerly known as BioLife Cell Bank, Inc. (the “Company”), and (the “Participant”).
AMENDMENT, WAIVER AND JOINDER TO THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • January 15th, 2016 • AveXis, Inc. • Biological products, (no disgnostic substances)
This Amendment, Waiver and Joinder (this “Amendment”), effective as of October 13, 2015 (the “Effective Date”) to the Third Amended and Restated Investor Rights Agreement, dated September 3, 2015 (the “Investor Rights Agreement”), is made by and among AveXis, Inc., a Delaware corporation (the “Company”), PBM Capital Investments, LLC, a Delaware limited liability company (“PBM”), White Rock Capital Partners, LP, a Texas limited partnership (“White Rock”), NRM VII Holdings I, LLC, a Virginia limited liability company (“NRM”), the individuals listed on Exhibit A hereto (the “Co-Investors”), the other Investors (as defined in the Investor Rights Agreement) and the Key Holders (as defined in the Investor Rights Agreement); provided, however, that Sections 2(a), 2(e), 2(f), 3(a)(ii), 5 and 6 hereof shall be effective as of January 15, 2016 (the “White Rock and NRM Effective Date”).
AVEXIS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • January 15th, 2016 • AveXis, Inc. • Biological products, (no disgnostic substances) • Ohio
This Employment Agreement (the “Agreement”) is entered into as of January 1, 2016, by and between Dr. Brian K. Kaspar, Ph.D. (the “Executive”) and AveXis, Inc., a Delaware Corporation (the “Company”).
